Actively Recruiting
Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients
Led by Xiaotong Hou · Updated on 2025-03-06
534
Participants Needed
1
Research Sites
148 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is: Does reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogenic shock as part of their regular medical care will have their data collected, including information about their vasopressor use and mortality outcomes, over the course of the study.
CONDITIONS
Official Title
Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults (≥18 years) with cardiogenic shock needing VA-ECMO support
- First-time ECMO initiation
- Venoarterial ECMO (VA-ECMO) as the initial mode of support
You will not qualify if you...
- Age under 18 years
- Severe pulmonary hypertension
- Vasopressor use for reasons other than shock (e.g., bleeding, post-cardiopulmonary bypass vasoplegia)
- Severe missing data
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China, 100029
Actively Recruiting
Research Team
X
Xiaotong Hou, MD
CONTACT
C
Chenglong Li, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here